AstraZeneca and Daiichi Sankyo fail to win NICE recommendation for Enhertu, call for change to review process

The United Kingdom’s drug pricing watchdog has officially declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu for HER2-low breast cancer in the UK, noting that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Diabetes-Related Eye Disease Remains High in the U.S.

The number of Americans with diabetes-related eye disease remains high, according to a nationally representative sample of data from the National Health and Nutrition Examination

June 16, 2023

Monthly IV version of Leqembi set for FDA review by next year – Pharmaceutical Technology

Leqembi won full FDA approval last July as a 100mg/mL injection for intravenous (IV) use as Eisai and Biogen pursue a monthly dosing regimen. Image

June 10, 2024

Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancer

Merck is halting a Phase III trial in non-small cell lung cancer (NSCLC) after its Keytruda-Lynparza combo flunked one of the primary endpoints in an

December 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.